



## Clinical trial results:

### A Multicenter, Open-label, Phase 1B/2 Study to Evaluate Safety and Efficacy of Avelumab (MSB0010718C) in Combination With Chemotherapy With or Without Other Anti-cancer Immunotherapies As First-line Treatment in Subjects With Advanced Malignancies

#### Summary

EudraCT number	2017-001741-27
Trial protocol	CZ ES HU GB IT
Global end of trial date	20 December 2022

#### Results information

Result version number	v1 (current)
This version publication date	29 June 2023
First version publication date	29 June 2023

#### Trial information

##### Trial identification

Sponsor protocol code	B9991023
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03317496
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 March 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	20 December 2022
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To assess DLT rate and objective response rate (ORR) of avelumab in combination with chemotherapy, as first-line treatment in subjects with locally advanced or metastatic solid tumors.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 December 2017
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	60 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 6
Country: Number of subjects enrolled	Canada: 4
Country: Number of subjects enrolled	Czechia: 4
Country: Number of subjects enrolled	Hungary: 3
Country: Number of subjects enrolled	Italy: 12
Country: Number of subjects enrolled	Spain: 18
Country: Number of subjects enrolled	United Kingdom: 17
Country: Number of subjects enrolled	United States: 2
Worldwide total number of subjects	66
EEA total number of subjects	37

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	25
From 65 to 84 years	41
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted in 2 phases: Phase 1b (lead-in phase) and Phase 2 (cohort expansion phase). Phase 2 was conducted at the highest dose level of avelumab which was determined safe for subjects in Phase 1b.

### Pre-assignment

Screening details:

Phase 1b lead-in: 49 subjects signed informed consent form (ICF). 18 subjects did not meet eligibility criteria and not enrolled, 31 subjects enrolled and assigned to treatment. Phase 2: 52 subjects signed ICF. 16 subjects did not meet eligibility criteria and not enrolled, 36 subjects enrolled, 1 was not assigned to treatment and 35 assigned to treatment

### Period 1

Period 1 title	Overall study
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin

Arm description:

Subjects with advanced non-squamous non-small cell lung cancer (NSCLC) received avelumab 800 milligrams (mg) as an intravenous (IV) infusion over 1 hour every 3 weeks (Q3W) in combination with IV infusion of pemetrexed 500 milligram per square meter ( $\text{mg}/\text{m}^2$ ) and carboplatin dose at area under curve (AUC) 5 (carboplatin dose  $[\text{mg}] = \text{target AUC} \times \text{glomerular filtration rate} [\text{GFR}] \text{ milliliter per minute } [\text{mL}/\text{min}] + 25$ , and maximum carboplatin dose = target AUC  $[\text{mg} \times \text{min}/\text{mL}] \times 150 \text{ mL}/\text{min}$ ) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received an IV infusion of pemetrexed 500 milligram per square meter ( $\text{mg}/\text{m}^2$ ) over 10 minutes on Day 1 of each 21-day cycle. It was administered for a maximum of 4 to 6 cycles. Maintenance therapy with pemetrexed was administered at the discretion of the Investigator.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received carboplatin dose at area under curve (AUC) 5 (carboplatin dose  $[\text{mg}] = \text{target AUC} \times \text{glomerular filtration rate } [\text{GFR}] \text{ milliliter per minute } [\text{mL}/\text{min}] + 25$ , and maximum carboplatin dose = target AUC  $[\text{mg} \times \text{min}/\text{mL}] \times 150 \text{ mL}/\text{min}$ ) on Day 1 of each 21-day cycle. It was administered for a maximum of 4 to 6 cycles.

Investigational medicinal product name	Avelumab 800mg
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use, Intravenous use

**Dosage and administration details:**

Subjects received avelumab 800 mg as an IV infusion over 1 hour every three weeks on Day 1 of each 21-day cycle.

<b>Arm title</b>	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin
------------------	---

**Arm description:**

Subjects (cisplatin-eligible) with urothelial cancer (UC) received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Avelumab 800mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received avelumab 800 mg as an IV infusion over 1 hour every three weeks on Day 1 of each 21-day cycle.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received an IV administration of cisplatin 70 mg/m<sup>2</sup> over 60 minutes on Day 1 of each 21-day cycle.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use, Intravenous use

**Dosage and administration details:**

Subjects received an IV administration of gemcitabine 1000 mg/m<sup>2</sup> over 30 minutes on Day 1 and 8 of each 21-day cycle.

<b>Arm title</b>	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
------------------	---

**Arm description:**

Subjects with advanced NSCLC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV infusion of pemetrexed 500 mg/m<sup>2</sup> and carboplatin dose at AUC 5 (carboplatin dose [mg] = target AUC \* GFR mL/min + 25), and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Avelumab 1200mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received avelumab 1200 mg as an IV infusion over 1 hour every three weeks on Day 1 of each

21-day cycle.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received carboplatin dose at area under curve (AUC) 5 (carboplatin dose [mg] = target AUC \* glomerular filtration rate [GFR] milliliter per minute [mL/min] + 25, and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. It was administered for a maximum of 4 to 6 cycles.

Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received an IV infusion of pemetrexed 500 milligram per square meter (mg/m<sup>2</sup>) over 10 minutes on Day 1 of each 21-day cycle. It was administered for a maximum of 4 to 6 cycles.

<b>Arm title</b>	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
------------------	---

Arm description:

Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first. Participants from both Phase 1b and Phase 2 Avelumab 1200 mg + Gemcitabine/Cisplatin were included in this arm.

Arm type	Experimental
Investigational medicinal product name	Avelumab 1200mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 1200 mg as an IV infusion over 1 hour every three weeks on Day 1 of each 21-day cycle.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received an IV administration of cisplatin 70 mg/m<sup>2</sup> over 60 minutes on Day 1 of each 21-day cycle.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received an IV administration of gemcitabine 1000 mg/m<sup>2</sup> over 30 minutes on Day 1 and 8 of each 21-day cycle.

Number of subjects in period 1	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
Started	6	13	6
Completed	6	13	6

Number of subjects in period 1	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
Started	41
Completed	41

## Period 2

Period 2 title	Phase 1b Lead-in: Treatment
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin

### Arm description:

Subjects with advanced non-squamous non-small cell lung cancer (NSCLC) received avelumab 800 milligrams (mg) as an intravenous (IV) infusion over 1 hour every 3 weeks (Q3W) in combination with IV infusion of pemetrexed 500 milligram per square meter (mg/m<sup>2</sup>) and carboplatin dose at area under curve (AUC) 5 (carboplatin dose [mg] = target AUC \* glomerular filtration rate[GFR] milliliter per minute [mL/min] + 25, and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Avelumab 800mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use, Intravenous use

### Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every three weeks on Day 1 of each 21-day cycle.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received carboplatin dose at area under curve (AUC) 5 (carboplatin dose [mg] = target AUC \* glomerular filtration rate [GFR] milliliter per minute [mL/min] + 25, and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. It was administered for a maximum of 4 to 6 cycles.

Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received an IV infusion of pemetrexed 500 milligram per square meter (mg/m<sup>2</sup>) over 10 minutes on Day 1 of each 21-day cycle. It was administered for a maximum of 4 to 6 cycles.

Maintenance therapy with pemetrexed was administered at the discretion of the Investigator.

<b>Arm title</b>	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin
------------------	---

**Arm description:**

Subjects (cisplatin-eligible) with urothelial cancer (UC) received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Avelumab 800mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received avelumab 800 mg as an IV infusion over 1 hour every three weeks on Day 1 of each 21-day cycle.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Subjects received an IV administration of cisplatin 70 mg/m<sup>2</sup> over 60 minutes on Day 1 of each 21-day cycle.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use, Intravenous use

**Dosage and administration details:**

Subjects received an IV administration of gemcitabine 1000 mg/m<sup>2</sup> over 30 minutes on Day 1 and 8 of each 21-day cycle.

<b>Arm title</b>	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
------------------	---

**Arm description:**

Subjects with advanced NSCLC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV infusion of pemetrexed 500 mg/m<sup>2</sup> and carboplatin dose at AUC 5 (carboplatin dose [mg] = target AUC \* GFR mL/min + 25), and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
----------	--------------



Investigational medicinal product name	Avelumab 1200mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 1200 mg as an IV infusion over 1 hour every three weeks on Day 1 of each 21-day cycle.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received carboplatin dose at area under curve (AUC) 5 (carboplatin dose [mg] = target AUC \* glomerular filtration rate [GFR] milliliter per minute [mL/min] + 25, and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. It was administered for a maximum of 4 to 6 cycles.

Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received an IV infusion of pemetrexed 500 milligram per square meter (mg/m<sup>2</sup>) over 10 minutes on Day 1 of each 21-day cycle. It was administered for a maximum of 4 to 6 cycles.

<b>Arm title</b>	Phase 1b Lead-in: Avelumab 1200 mg + Gemcitabine/Cisplatin
------------------	--

Arm description:

Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Avelumab 1200mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 1200 mg as an IV infusion over 1 hour every three weeks on Day 1 of each 21-day cycle.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received an IV administration of gemcitabine 1000 mg/m<sup>2</sup> over 30 minutes on Day 1 and 8 of each 21-day cycle.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

---

**Dosage and administration details:**

Subjects received an IV administration of gemcitabine 1000 mg/m<sup>2</sup> over 30 minutes on Day 1 and 8 of each 21-day cycle.

Number of subjects in period 2 <sup>[1]</sup>	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
Started	6	13	6
Completed	0	0	0
Not completed	6	13	6
Physician decision	-	1	-
Global deterioration of health status	-	-	1
Death	-	-	1
Progressive Disease	1	6	3
Adverse event	3	4	1
Study terminated by sponsor	-	1	-
Unspecified	2	1	-

Number of subjects in period 2 <sup>[1]</sup>	Phase 1b Lead-in: Avelumab 1200 mg + Gemcitabine/Cisplatin
Started	6
Completed	0
Not completed	6
Physician decision	-
Global deterioration of health status	-
Death	-
Progressive Disease	4
Adverse event	1
Study terminated by sponsor	1
Unspecified	-

---

**Notes:**

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: The number of subjects specified equals the number of subjects entered for this period.

**Period 3**

Period 3 title	Phase 1b Lead-in: Follow-up
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	No
<b>Arm title</b>	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin

## Arm description:

Subjects with advanced non-squamous non-small cell lung cancer (NSCLC) received avelumab 800 milligrams (mg) as an intravenous (IV) infusion over 1 hour every 3 weeks (Q3W) in combination with IV infusion of pemetrexed 500 milligram per square meter (mg/m<sup>2</sup>) and carboplatin dose at area under curve (AUC) 5 (carboplatin dose [mg] = target AUC \* glomerular filtration rate[GFR] milliliter per minute [mL/min] + 25, and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Arm title</b>	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin
------------------	---

## Arm description:

Subjects (cisplatin-eligible) with urothelial cancer (UC) received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Arm title</b>	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
------------------	---

## Arm description:

Subjects with advanced NSCLC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV infusion of pemetrexed 500 mg/m<sup>2</sup> and carboplatin dose at AUC 5 (carboplatin dose [mg] = target AUC \* GFR mL/min + 25), and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Arm title</b>	Phase 1b Lead-in: Avelumab 1200 mg + Gemcitabine/Cisplatin
------------------	--

## Arm description:

Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 3	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
Started	6	12	5
Completed	0	0	0
Not completed	6	12	5
Consent withdrawn by subject	-	-	1
Death	3	8	4
Study terminated by sponsor	2	3	-
Unspecified	-	1	-
Lost to follow-up	1	-	-

Number of subjects in period 3	Phase 1b Lead-in: Avelumab 1200 mg + Gemcitabine/Cisplatin
Started	6
Completed	0
Not completed	6
Consent withdrawn by subject	-
Death	4
Study terminated by sponsor	1
Unspecified	1
Lost to follow-up	-

#### Period 4

Period 4 title	Phase 2: Treatment
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

#### Arms

<b>Arm title</b>	Phase 2: Avelumab 1200 mg + Gemcitabine/Cisplatin
Arm description: Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m <sup>2</sup> and gemcitabine 1000 mg/m <sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Arm type	Experimental

Investigational medicinal product name	Avelumab 1200mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 1200 mg as an IV infusion over 1 hour every three weeks on Day 1 of each 21-day cycle.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion, Concentrate for solution for injection/infusion
Routes of administration	Intravenous use, Intravenous use

Dosage and administration details:

Subjects received an IV administration of cisplatin 70 mg/m<sup>2</sup> over 60 minutes on Day 1 of each 21-day cycle.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received an IV administration of gemcitabine 1000 mg/m<sup>2</sup> over 30 minutes on Day 1 and 8 of each 21-day cycle.

Number of subjects in period 4	Phase 2: Avelumab 1200 mg + Gemcitabine/Cisplatin
Started	35
Completed	33
Not completed	2
Consent withdrawn by subject	1
Death	1

## Period 5

Period 5 title	Phase 2: Follow-up
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	Phase 2: Avelumab 1200 mg + Gemcitabine/Cisplatin
Arm description:	
Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m <sup>2</sup> and gemcitabine 1000 mg/m <sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 5</b>	Phase 2: Avelumab 1200 mg + Gemcitabine/Cisplatin
Started	33
Completed	0
Not completed	33
Death	24
Study terminated by sponsor	7
Unspecified	1
Lost to follow-up	1

## Baseline characteristics

### Reporting groups

Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin
-----------------------	--

#### Reporting group description:

Subjects with advanced non-squamous non-small cell lung cancer (NSCLC) received avelumab 800 milligrams (mg) as an intravenous (IV) infusion over 1 hour every 3 weeks (Q3W) in combination with IV infusion of pemetrexed 500 milligram per square meter ( $\text{mg}/\text{m}^2$ ) and carboplatin dose at area under curve (AUC) 5 (carboplatin dose  $[\text{mg}] = \text{target AUC} \times \text{glomerular filtration rate} [\text{GFR}]$  milliliter per minute  $[\text{mL}/\text{min}] + 25$ , and maximum carboplatin dose = target AUC  $[\text{mg} \times \text{min}/\text{mL}] \times 150 \text{ mL}/\text{min}$ ) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin
-----------------------	---

#### Reporting group description:

Subjects (cisplatin-eligible) with urothelial cancer (UC) received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin  $70 \text{ mg}/\text{m}^2$  and gemcitabine  $1000 \text{ mg}/\text{m}^2$  on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
-----------------------	---

#### Reporting group description:

Subjects with advanced NSCLC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV infusion of pemetrexed  $500 \text{ mg}/\text{m}^2$  and carboplatin dose at AUC 5 (carboplatin dose  $[\text{mg}] = \text{target AUC} \times \text{GFR mL}/\text{min} + 25$ ), and maximum carboplatin dose = target AUC  $[\text{mg} \times \text{min}/\text{mL}] \times 150 \text{ mL}/\text{min}$ ) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
-----------------------	--

#### Reporting group description:

Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin  $70 \text{ mg}/\text{m}^2$  and gemcitabine  $1000 \text{ mg}/\text{m}^2$  on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first. Participants from both Phase 1b and Phase 2 Avelumab 1200 mg + Gemcitabine/Cisplatin were included in this arm.

Reporting group values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
Number of subjects	6	13	6
Age categorical Units: Subjects			
Adults (18-64 years)	1	7	3
From 65-84 years	5	6	3
Age Continuous Units: Years			
arithmetic mean	69.67	63.00	64.67
standard deviation	$\pm 6.65$	$\pm 10.15$	$\pm 9.16$
Sex: Female, Male Units: Subjects			
Female	2	5	0

Male	4	8	6
------	---	---	---

Race (NIH/OMB)			
Units: Subjects			
Asian	0	1	1
Black or African American	0	1	0
White	6	11	5
Unknown or not reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	1	0
Not Hispanic or Latino	6	11	6
Unknown or Not Reported	0	1	0

<b>Reporting group values</b>	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin	Total	
Number of subjects	41	66	
Age categorical			
Units: Subjects			
Adults (18-64 years)	14	25	
From 65-84 years	27	41	
Age Continuous			
Units: Years			
arithmetic mean	65.24		
standard deviation	± 10.48	-	
Sex: Female, Male			
Units: Subjects			
Female	10	17	
Male	31	49	
Race (NIH/OMB)			
Units: Subjects			
Asian	1	3	
Black or African American	0	1	
White	37	59	
Unknown or not reported	3	3	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	1	
Not Hispanic or Latino	37	60	
Unknown or Not Reported	4	5	



## End points

### End points reporting groups

Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin
Reporting group description: Subjects with advanced non-squamous non-small cell lung cancer (NSCLC) received avelumab 800 milligrams (mg) as an intravenous (IV) infusion over 1 hour every 3 weeks (Q3W) in combination with IV infusion of pemetrexed 500 milligram per square meter (mg/m <sup>2</sup> ) and carboplatin dose at area under curve (AUC) 5 (carboplatin dose [mg] = target AUC * glomerular filtration rate[GFR] milliliter per minute [mL/min] + 25, and maximum carboplatin dose = target AUC [mg*min/mL] * 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin
Reporting group description: Subjects (cisplatin-eligible) with urothelial cancer (UC) received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m <sup>2</sup> and gemcitabine 1000 mg/m <sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
Reporting group description: Subjects with advanced NSCLC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV infusion of pemetrexed 500 mg/m <sup>2</sup> and carboplatin dose at AUC 5 (carboplatin dose [mg] = target AUC * GFR mL/min + 25), and maximum carboplatin dose = target AUC [mg*min/mL] * 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
Reporting group description: Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m <sup>2</sup> and gemcitabine 1000 mg/m <sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first. Participants from both Phase 1b and Phase 2 Avelumab 1200 mg + Gemcitabine/Cisplatin were included in this arm.	
Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin
Reporting group description: Subjects with advanced non-squamous non-small cell lung cancer (NSCLC) received avelumab 800 milligrams (mg) as an intravenous (IV) infusion over 1 hour every 3 weeks (Q3W) in combination with IV infusion of pemetrexed 500 milligram per square meter (mg/m <sup>2</sup> ) and carboplatin dose at area under curve (AUC) 5 (carboplatin dose [mg] = target AUC * glomerular filtration rate[GFR] milliliter per minute [mL/min] + 25, and maximum carboplatin dose = target AUC [mg*min/mL] * 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin
Reporting group description: Subjects (cisplatin-eligible) with urothelial cancer (UC) received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m <sup>2</sup> and gemcitabine 1000 mg/m <sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
Reporting group description: Subjects with advanced NSCLC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in	

combination with IV infusion of pemetrexed 500 mg/m<sup>2</sup> and carboplatin dose at AUC 5 (carboplatin dose [mg] = target AUC \* GFR mL/min + 25), and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 1b Lead-in: Avelumab 1200 mg + Gemcitabine/Cisplatin
-----------------------	--

Reporting group description:

Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin
-----------------------	--

Reporting group description:

Subjects with advanced non-squamous non-small cell lung cancer (NSCLC) received avelumab 800 milligrams (mg) as an intravenous (IV) infusion over 1 hour every 3 weeks (Q3W) in combination with IV infusion of pemetrexed 500 milligram per square meter (mg/m<sup>2</sup>) and carboplatin dose at area under curve (AUC) 5 (carboplatin dose [mg] = target AUC \* glomerular filtration rate[GFR] milliliter per minute [mL/min] + 25, and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin
-----------------------	---

Reporting group description:

Subjects (cisplatin-eligible) with urothelial cancer (UC) received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
-----------------------	---

Reporting group description:

Subjects with advanced NSCLC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV infusion of pemetrexed 500 mg/m<sup>2</sup> and carboplatin dose at AUC 5 (carboplatin dose [mg] = target AUC \* GFR mL/min + 25), and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 1b Lead-in: Avelumab 1200 mg + Gemcitabine/Cisplatin
-----------------------	--

Reporting group description:

Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 2: Avelumab 1200 mg + Gemcitabine/Cisplatin
-----------------------	---

Reporting group description:

Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 2: Avelumab 1200 mg + Gemcitabine/Cisplatin
-----------------------	---

Reporting group description:

Subjects (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

**Primary: Phase 1b Lead-in: Number of Subjects With Dose-Limiting Toxicities (DLT)**

End point title	Phase 1b Lead-in: Number of Subjects With Dose-Limiting Toxicities (DLT) <sup>[1]</sup>
-----------------	---

## End point description:

DLTs=occurrence of any AEs attributable to study treatment in first 2 treatment cycles:Hematologic: grade(G)4 neutropenia lasting >7days;febrile neutropenia with body temperature  $\geq 38$  degree Celsius for >1hour;  $G \geq 3$  neutropenic infection(absolute neutrophil count  $< 1.0 \times 10^9/L$ ), $G \geq 3$  thrombocytopenia (platelet count $< 50.0 - 25.0 \times 10^9/L$ )with bleeding; $G 4$  thrombocytopenia( $PC < 25.0 \times 10^9/L$ ), $G 4$  anemia(life-threatening).Non-hematologic: any  $G 4$  toxicities; $G 3$  toxicities persisting for >3days despite medical treatment(nausea,vomiting,diarrhea)except endocrinopathies controlled with hormonal therapy;ALT/AST  $> 3 \times$ upper limit of normal(ULN)if normal at baseline or  $2 \times$ Baseline( $> ULN$  at baseline)with total bilirubin  $> 2 \times ULN$  and alkaline phosphatase  $< 2 \times ULN$ ; $G 3$  QTcF prolongation after correction of any reversible cause(electrolyte abnormalities/hypoxia).Delay of  $\geq 3$ weeks in scheduled administration/failure to deliver 75% of doses due to toxicities attributable to any study treatment. DLT-evaluable analysis set.

End point type	Primary
----------------	---------

## End point timeframe:

Day 1 up to Week 6 (first 2 treatment cycles; 1 cycle = 21 days)

## Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for this endpoint.

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	12	6	6
Units: Subjects	0	1	0	1

**Statistical analyses**

No statistical analyses for this end point

**Primary: Percentage of Subjects With Confirmed Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment**

End point title	Percentage of Subjects With Confirmed Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment <sup>[2]</sup>
-----------------	--

## End point description:

OR: complete response(CR) or partial response(PR)determined by investigator according to RECIST v1.1 from date of first dose of study treatment until date of first documentation of progressive disease(PD),confirmed by repeat assessments performed no less than 4 weeks after first response. CR: disappearance of target/non-target lesions, with exception of nodal disease and normalization of tumor markers. All nodes, target and non-target must have short axis measures  $< 10$  mm. PR:  $\geq 30\%$  decrease in sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference baseline sum of diameters. Non-target lesions must be non-PD. PD:  $\geq 20\%$  increase in sum of diameters of target lesions, taking as reference smallest sum on study,relative increase of 20%, sum must also demonstrate an absolute increase of at least 5mm, appearance of 1 or more new lesions was considered PD. FAS:all subjects who received at least 1 dose of any study drug.

End point type	Primary
----------------	---------

End point timeframe:

From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 5 years approximately)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be analyzed for this endpoint.

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	41
Units: Percentage of Subjects				
number (confidence interval 95%)	50.0 (11.8 to 88.2)	53.8 (25.1 to 80.8)	33.3 (4.3 to 77.7)	39.0 (24.2 to 55.5)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
-----------------	---

End point description:

Adverse event (AE) was any untoward medical occurrence in a subject who received any study drug without regard to possibility of causal relationship. Serious adverse event was any untoward medical occurrence that at any dose resulted in any of following outcomes/deemed significant for any other reason: death; initial /prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. Safety analysis set included all subjects who received at least 1 dose of any study drug. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5 years approximately)

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	41
Units: Subjects				

TEAEs	6	13	6	40
Serious TEAEs	3	9	5	20

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Treatment Related TEAEs

End point title	Number of Subjects With Treatment Related TEAEs
-----------------	---

End point description:

A treatment related AE included AEs related to at least one study drug in the combination. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. Relatedness to study drug was assessed by the investigator. Safety analysis set included all subjects who received at least 1 dose of any study drug. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5 years approximately)

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	41
Units: Subjects	6	12	6	40

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) v 4.03

End point title	Number of Subjects With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) v 4.03
-----------------	---

End point description:

AE was any untoward medical occurrence in a subject who received any study drug without regard to possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. TEAEs were graded by the investigator using NCI CTCAE v 4.03 as Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. In this outcome

measure, number of subjects with grade 3 or higher TEAEs were reported. Safety analysis set included all subjects who received at least 1 dose of any study drug. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
End point timeframe:	
From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5 years approximately)	

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	37
Units: Subjects	5	12	6	40

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Grade 3 or Higher Laboratory Abnormalities by CTCAE Grade

End point title	Number of Subjects With Grade 3 or Higher Laboratory Abnormalities by CTCAE Grade
-----------------	---

End point description:

The number of subjects with laboratory abnormalities of any Grade classified according to NCI CTCAE toxicity grading v4.03 were summarized: hematology (anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell decreased) and clinical chemistry (alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, creatinine phosphokinase [cpk] increased, creatinine increased, gamma-glutamyl transferase [ggT] increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, serum amylase increased and lipase increased). As per NCI CTCAE toxicity grading v4.03, Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening; Grade 5=death. Safety analysis set.

End point type	Secondary
End point timeframe:	
From screening up to 90 days after last dose of study drug (maximum up to 5 years approximately)	

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	40

Units: Subjects				
ALANINE AMINOTRANSFERAS E INCREASED	1	1	0	3
ALKALINE PHOSPHATASE INCREASED	0	0	0	1
ASPARTATE AMINOTRANSFERAS E INCREASED	1	1	0	2
BLOOD BILIRUBIN INCREASED	0	1	0	0
CPK INCREASED	0	0	0	1
CREATININE INCREASED	1	1	0	0
GGT INCREASED	0	2	1	4
HYPERGLYCEMIA	2	2	0	4
HYPERKALEMIA	0	1	0	2
HYPOKALEMIA	1	0	0	5
HYPONATREMIA	0	2	1	4
LIPASE INCREASED	1	2	1	4
SERUM AMYLASE INCREASED	0	2	0	4
HYPOPHOSPHATEMIA	2	0	1	3
HYPOMAGNESEMIA	0	0	0	2
HYPOCALCEMIA	2	0	0	1
HYPERTRIGLYCERIDEMIA	0	3	0	2
HYPERNATREMIA	0	0	0	1
HYPERMAGNESEMIA	0	0	0	1
HYPERCALCEMIA	0	0	0	1
ANEMIA	2	5	0	6
LYMPHOCYTE COUNT DECREASED	3	5	1	7
LYMPHOCYTE COUNT INCREASED	0	0	0	1
NEUTROPHIL COUNT DECREASED	3	8	3	0
PLATELET COUNT DECREASED	3	2	0	11
WHITE BLOOD CELL DECREASED	2	7	3	21

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum Concentration of Avelumab

End point title	Serum Concentration of Avelumab
-----------------	---------------------------------

End point description:

The lower limit of quantification (LLOQ) for avelumab was 0.2 micrograms per milliliter. Pharmacokinetic concentration analysis set was subset of safety analysis set and included subjects who had at least one concentration measurement for avelumab or other study drugs which they were assigned to receive. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan. Overall number of subjects analyzed= subjects evaluable for this outcome measure. Number analyzed= subjects evaluable at specified time point. Here 99999 signifies not applicable/not estimable since data was not estimable due to low number of subjects analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose, 1 hour post-dose on Day 1 of Cycle 1, 2, 3, 6, 10, 14; 336 hours post-dose on Day 15 of Cycle 1, 2, 3 (each cycle of 21 days)

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	40
Units: Micrograms per milliliter				
geometric mean (geometric coefficient of variation)				
Cycle 1/Day 1- 1 hour (n= 4, 10, 1, 32)	173.3 (± 26)	172.2 (± 18)	284.1 (± 33)	300.2 (± 32)
Cycle 1/Day 15- 336 hours (n= 6,12,6,34)	12.32 (± 47)	9.570 (± 92)	16.51 (± 68)	14.71 (± 74)
Cycle 2/Day 1- pre-dose (n= 6, 8, 6, 24)	4.780 (± 44)	3.754 (± 115)	4.328 (± 332)	5.013 (± 196)
Cycle 2/Day 1- 1 hour (n= 4, 8, 4, 20)	164.2 (± 33)	197.0 (± 18)	104.5 (± 1474)	311.9 (± 36)
Cycle 2/Day 15- 336 hours (n= 6, 8, 5, 27)	16.87 (± 24)	13.55 (± 33)	16.82 (± 137)	18.66 (± 75)
Cycle 3/Day 1- pre-dose (n= 5, 9, 5, 19)	8.122 (± 40)	5.651 (± 75)	4.878 (± 662)	6.771 (± 104)
Cycle 3/Day 1- 1 hour (n= 4, 7, 4, 11)	147.0 (± 35)	204.0 (± 28)	93.81 (± 2989)	296.8 (± 36)
Cycle 3/Day 15- 336 hours (n= 5, 7, 6, 16)	19.40 (± 14)	17.15 (± 40)	26.17 (± 74)	22.55 (± 79)
Cycle 6/Day 1- pre-dose (n= 5, 7, 4, 8)	11.38 (± 24)	9.518 (± 65)	10.86 (± 165)	10.39 (± 233)
Cycle 6/Day 1- 1 hour (n= 4, 7, 3, 12)	92.53 (± 203)	208.3 (± 23)	245.4 (± 6)	344.0 (± 27)
Cycle 10/Day 1- pre-dose (n= 4, 6, 1, 14)	9.523 (± 33)	8.695 (± 115)	6.620 (± 99999)	18.55 (± 58)
Cycle 10/Day 1- 1 hour (n= 3, 6, 1, 6)	179.0 (± 38)	222.0 (± 27)	6.040 (± 99999)	242.9 (± 121)
Cycle 14/Day 1- pre-dose (n=3, 4, 2, 8)	14.97 (± 28)	13.37 (± 77)	12.24 (± 523)	16.49 (± 57)
Cycle 14/Day 1- 1 hour (n=3, 4, 2, 5)	215.3 (± 20)	216.6 (± 22)	29.05 (± 20555)	402.2 (± 19)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies for Avelumab

End point title	Number of Subjects With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies for Avelumab
End point description:	
Blood samples were collected for assessment of avelumab ADAs using a tiered assay and confirmed positive samples were tested for neutralizing antibodies (nAb). No positive ADA results at any time point; ADA-negative patients (titer < cutpoint). Here 99999 signifies not applicable/not estimable since data for NAB was not collected due to low observed immunogenicity.	
End point type	Secondary
End point timeframe:	
From first dose of study drug up to last dose of study drug (maximum up to 5 years approximately)	



End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	41
Units: Subjects				
ADA ever positive (n=6,13,6,41)	0	5	1	9
NAB ever positive (n=0,0,0,0)	99999	99999	99999	99999

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression Free Survival (PFS) as per RECIST v 1.1 by Investigator Assessment

End point title	Progression Free Survival (PFS) as per RECIST v 1.1 by Investigator Assessment
-----------------	--

End point description:

PFS was defined as the time from the date of first dose of study treatment to the date of the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurred first. PD = at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or appearance of one or more new lesions was considered progression. The median duration of OS was planned not to derive for less than (<) 10 subjects. Here 99999 signifies not applicable/not estimable since data was not estimable due to low number of subjects analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 5 years approximately)

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	41
Units: Months				
median (confidence interval 95%)	99999 (99999 to 99999)	9.8 (2.2 to 99999)	99999 (99999 to 99999)	5.4 (2.9 to 6.0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS was defined as the time from the first dose of study treatment to the date of death from any cause. Subjects who were alive at the study end date or the last visit date available were censored at the date of last contact. The median duration of OS was planned not to derive for less than (<) 10 subjects. Here 99999 signifies not applicable/not estimable since data was not estimable due to low number of subjects analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study treatment until death due to any cause (maximum up to 5 years approximately)

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	41
Units: Months				
median (confidence interval 95%)	99999 (99999 to 99999)	18.1 (5.0 to 99999)	99999 (99999 to 99999)	15.1 (8.7 to 22.0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DOR) as per RECIST v 1.1 by Investigator Assessment

End point title	Duration of Response (DOR) as per RECIST v 1.1 by Investigator Assessment
-----------------	---

End point description:

DOR was defined as time from first documentation of objective response (confirmed CR or PR) to the date of first PD documentation or death due to any cause, whichever occurs first. Per RECIST v1.1, CR = disappearance of target and non-target lesions, with exception of nodal disease and normalization of tumor markers. Target and non-target nodes must have short axis measures <10 mm. PR = at least a 30% decrease in the sum of measures (diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference baseline sum of diameters. Non-target lesions must be non-PD. PD = at least a 20% increase in sum of diameters of target lesions, moreover, the sum must demonstrate an absolute increase of at least 5 mm or appearance of one or more new lesions was considered progression. Median DOR was not derived for < 5 subjects. Here 99999 signifies not applicable/not estimable due to low number of subjects analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of first documented response to date of first documented PD or death due to any cause, whichever occurred first (maximum up to 5 years approximately)

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	2	16
Units: Months				
median (confidence interval 95%)	99999 (99999 to 99999)	9.6 (4.0 to 99999)	99999 (99999 to 99999)	99999 (4.2 to 99999)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Absolute Value of Tumor Mutational Burden (TMB) in Tumor Tissue

End point title	Absolute Value of Tumor Mutational Burden (TMB) in Tumor Tissue
-----------------	---

End point description:

Mutational load within tumor tissue was defined as number per megabase of the genome, coding, base substitution, and indel mutations present in the sample. Mutational load was determined in whole blood samples using next generation deoxyribonucleic acid (DNA) sequencing followed by computational analysis. The tumor tissue based biomarker analysis set was subset of the safety analysis set and included subjects who had at least one baseline and one on-treatment biomarker assessment for the same biomarker. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 of Cycle 1

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	13	5	39
Units: Mutations per megabase				
arithmetic mean (standard deviation)	4.3 (± 6.75)	2.8 (± 2.76)	4.4 (± 5.15)	2.5 (± 2.88)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time-to-Tumor Response (TTR) as per RECIST v 1.1 by Investigator Assessment

End point title	Time-to-Tumor Response (TTR) as per RECIST v 1.1 by
-----------------	---

## End point description:

TTR was defined as the time from the date of first dose of study treatment to the first documentation of objective response (CR or PR) as assessed by investigator according to RECIST v 1.1. As per RECIST v 1.1, CR was defined as disappearance of all target and non-target lesions, with exception of nodal disease. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

End point type	Secondary
----------------	-----------

## End point timeframe:

From first dose of study treatment until first documentation of CR or PR (maximum up to 5 years approximately)

End point values	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2: Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	7	2	16
Units: Months				
median (full range (min-max))	2.8 (1.3 to 4.1)	1.4 (1.1 to 1.5)	1.3 (1.3 to 1.3)	1.5 (1.3 to 4.3)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Programmed Death-Ligand 1 (PD-L1) Expression

End point title	Number of Subjects With Programmed Death-Ligand 1 (PD-L1) Expression
-----------------	--

## End point description:

PD-L1 expression was determined using the Ventana PD-L1 SP263 IHC assay. PD-L1-positive status in UC cohorts was defined using an algorithm that combines assessments of PD-L1 staining on tumor and immune cells scored by pathologists and in NSCLC cohorts was defined as PD-L1 expression on  $\geq 1\%$  of tumor cells. PD-L1 expression at baseline and on-treatment were reported in this outcome measure. FAS included all subjects who received at least one dose of study drug. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline and Cycle 2 Day 8 (each cycle of 21 days)

<b>End point values</b>	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin	Phase 1b Lead-in+Phase 2:Avelumab 1200mg+Gemcitabine/Cisplatin
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	13	6	41
Units: Subjects				
Baseline- Positive PD-L1	0	6	1	28
Baseline- Negative PD-L1	4	7	4	13
Baseline- Unknown PD-L1	2	0	1	0
On-treatment (Cycle 2 Day 8)- Positive PD-L1	0	2	1	3
On-treatment (Cycle 2 Day 8)- Negative PD-L1	2	1	0	6
On-treatment (Cycle 2 Day 8)- Unknown PD-L1	4	10	5	32

### Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information

---

Timeframe for reporting adverse events:

All-cause mortality: From start of the treatment up to 90 days post last dose of study treatment, TEAEs and Serious TEAEs: From start of the treatment up to 30 days post last dose of study treatment (maximum of 5 years approximately)

---

Adverse event reporting additional description:

Same event may appear as both an AE and SAE. Safety set was evaluated. Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan.

TEAEs: events with onset dates occurring during on-treatment period (time from 1st dose of any study treatment and up to 30 days after last dose).

---

Assessment type	Non-systematic
-----------------	----------------

---

### Dictionary used

---

Dictionary name	MedDRA
-----------------	--------

---

Dictionary version	24.1
--------------------	------

---

### Reporting groups

---

Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin
-----------------------	--

---

Reporting group description:

Participants with advanced NSCLC received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV infusion of pemetrexed 500 mg/m<sup>2</sup> and carboplatin dose at AUC 5 (carboplatin dose [mg] = target AUC \* GFR mL/min + 25, and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

---

Reporting group title	Phase 1b and 2: Avelumab 1200 mg + Gemcitabine/Cisplatin
-----------------------	--

---

Reporting group description:

Participants (cisplatin-eligible) with UC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first. Participants from both Phase 1b and Phase 2 Avelumab 1200 mg + Gemcitabine/Cisplatin were included in this arm.

---

Reporting group title	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
-----------------------	---

---

Reporting group description:

Participants with advanced NSCLC received avelumab 1200 mg as an IV infusion over 1 hour Q3W in combination with IV infusion of pemetrexed 500 mg/m<sup>2</sup> and carboplatin dose at AUC 5 (carboplatin dose [mg] = target AUC \* GFR mL/min + 25), and maximum carboplatin dose = target AUC [mg\*min/mL] \* 150 mL/min) on Day 1 of each 21-day cycle. Pemetrexed/carboplatin were administered for a maximum of 4 to 6 cycles. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

---

Reporting group title	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin
-----------------------	---

---

Reporting group description:

Participants (cisplatin-eligible) with UC received avelumab 800 mg as an IV infusion over 1 hour Q3W in combination with IV administration of cisplatin 70 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> on Day 1 of each 21-day cycle with gemcitabine being administered on Day 1 and Day 8. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

---

<b>Serious adverse events</b>	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b and 2: Avelumab 1200 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 6 (50.00%)	20 / 41 (48.78%)	5 / 6 (83.33%)
number of deaths (all causes)	3	29	5
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Peripheral embolism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal			

disorders			
Haemoptysis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	2 / 6 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Infusion related reaction			



subjects affected / exposed	0 / 6 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Other	Additional description: Near drowning		
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrioventricular block			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			

subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Pancytopenia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Constipation			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal impairment			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fasciitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urosepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	5 / 41 (12.20%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			

subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bacteriuria</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infection</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>Hyperkalaemia</b>			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin		
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 13 (69.23%)		
number of deaths (all causes)	8		
number of deaths resulting from adverse events			
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>Neoplasm progression</b>			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Vascular disorders</b>			
<b>Peripheral embolism</b>			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Hypotension</b>			

subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Malaise			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sudden death			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthenia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Haemoptysis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Interstitial lung disease			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumothorax			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Pulmonary embolism			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Alanine aminotransferase increased			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Humerus fracture			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal fracture			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thoracic vertebral fracture			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Other	Additional description: Near drowning		



subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac disorders</b>			
Atrioventricular block			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial thrombosis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardiomyopathy			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bradycardia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Nervous system disorders</b>			
Cerebrovascular accident			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hydrocephalus			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			

subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Pancytopenia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaemia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subileus			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			

subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal impairment			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary retention			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Acute kidney injury			

subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fasciitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Urosepsis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		

Sepsis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Rhinovirus infection			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rectal abscess			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteriuria			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Phase 1b Lead-in: Avelumab 800 mg + Pemetrexed/Carboplatin	Phase 1b and 2: Avelumab 1200 mg + Gemcitabine/Cisplatin	Phase 1b Lead-in: Avelumab 1200 mg + Pemetrexed/Carboplatin
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 6 (100.00%)	40 / 41 (97.56%)	6 / 6 (100.00%)
<b>Vascular disorders</b>			
Deep vein thrombosis subjects affected / exposed	0 / 6 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Hypertension subjects affected / exposed	0 / 6 (0.00%)	6 / 41 (14.63%)	0 / 6 (0.00%)
occurrences (all)	0	14	0
Lymphoedema subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Superficial vein thrombosis subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Thrombosis subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>General disorders and administration site conditions</b>			
Pain subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Oedema peripheral subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	4	0
Mucosal inflammation subjects affected / exposed	1 / 6 (16.67%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Influenza like illness subjects affected / exposed	1 / 6 (16.67%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	2	0

Fatigue			
subjects affected / exposed	3 / 6 (50.00%)	15 / 41 (36.59%)	3 / 6 (50.00%)
occurrences (all)	3	36	5
Extravasation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	1 / 6 (16.67%)	1 / 41 (2.44%)	1 / 6 (16.67%)
occurrences (all)	1	1	1
Asthenia			
subjects affected / exposed	2 / 6 (33.33%)	11 / 41 (26.83%)	0 / 6 (0.00%)
occurrences (all)	5	39	0
Thirst			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	2 / 6 (33.33%)	11 / 41 (26.83%)	0 / 6 (0.00%)
occurrences (all)	3	16	0
Chills			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Immune system disorders			
Cytokine release syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	3
Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 6 (0.00%)	4 / 41 (9.76%)	1 / 6 (16.67%)
occurrences (all)	0	5	1

Dyspnoea			
subjects affected / exposed	2 / 6 (33.33%)	5 / 41 (12.20%)	2 / 6 (33.33%)
occurrences (all)	2	6	2
Dyspnoea exertional			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Haemoptysis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Hypoxia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	2 / 6 (33.33%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Productive cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)	4 / 41 (9.76%)	0 / 6 (0.00%)
occurrences (all)	0	4	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 6 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Depression			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	5	3
Insomnia			
subjects affected / exposed	2 / 6 (33.33%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
Irritability			



subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mood altered			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	4	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 6 (33.33%)	13 / 41 (31.71%)	1 / 6 (16.67%)
occurrences (all)	3	30	1
Amylase increased			
subjects affected / exposed	2 / 6 (33.33%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	3	5	0
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 6 (33.33%)	9 / 41 (21.95%)	0 / 6 (0.00%)
occurrences (all)	3	13	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 6 (0.00%)	8 / 41 (19.51%)	0 / 6 (0.00%)
occurrences (all)	0	12	0
Blood triglycerides increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood calcium increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Blood creatinine increased			
subjects affected / exposed	3 / 6 (50.00%)	13 / 41 (31.71%)	0 / 6 (0.00%)
occurrences (all)	5	28	13
Blood pressure increased			

subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	1 / 6 (16.67%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Blood bilirubin increased			
subjects affected / exposed	0 / 6 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Body temperature increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	7 / 41 (17.07%)	0 / 6 (0.00%)
occurrences (all)	0	15	0
Haemoglobin decreased			
subjects affected / exposed	0 / 6 (0.00%)	4 / 41 (9.76%)	0 / 6 (0.00%)
occurrences (all)	0	5	0
Lipase increased			
subjects affected / exposed	0 / 6 (0.00%)	2 / 41 (4.88%)	1 / 6 (16.67%)
occurrences (all)	0	4	1
Lymphocyte count decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Neutrophil count decreased			
subjects affected / exposed	0 / 6 (0.00%)	5 / 41 (12.20%)	0 / 6 (0.00%)
occurrences (all)	0	14	0
Platelet count decreased			
subjects affected / exposed	4 / 6 (66.67%)	9 / 41 (21.95%)	1 / 6 (16.67%)
occurrences (all)	15	18	1
Prothrombin time prolonged			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Troponin increased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 6 (0.00%)	7 / 41 (17.07%)	2 / 6 (33.33%)
occurrences (all)	0	7	2
White blood cell count decreased			
subjects affected / exposed	2 / 6 (33.33%)	6 / 41 (14.63%)	0 / 6 (0.00%)
occurrences (all)	12	30	0
Injury, poisoning and procedural complications			
Back injury			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Fall			
subjects affected / exposed	1 / 6 (16.67%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	1	3	0
Femur fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Pelvic fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Procedural pneumothorax			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Skin abrasion			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Urinary tract stoma complication			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Sinus bradycardia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Palpitations			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Intracardiac thrombus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Lethargy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ataxia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Cognitive disorder			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	6 / 41 (14.63%)	0 / 6 (0.00%)
occurrences (all)	0	6	0
Dizziness postural			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			

subjects affected / exposed	1 / 6 (16.67%)	5 / 41 (12.20%)	0 / 6 (0.00%)
occurrences (all)	1	6	0
Headache			
subjects affected / exposed	1 / 6 (16.67%)	2 / 41 (4.88%)	1 / 6 (16.67%)
occurrences (all)	2	3	1
Hypoaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Neuralgia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	1 / 6 (16.67%)
occurrences (all)	0	1	2
Presyncope			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Sciatica			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Taste disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	4	0
Blood and lymphatic system disorders			
Lymphopenia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Neutropenia			
subjects affected / exposed	3 / 6 (50.00%)	23 / 41 (56.10%)	4 / 6 (66.67%)
occurrences (all)	14	74	12
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	20 / 41 (48.78%)	4 / 6 (66.67%)
occurrences (all)	0	56	8

Thrombocytosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Anaemia subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 10	26 / 41 (63.41%) 94	1 / 6 (16.67%) 1
Haemolytic anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	1 / 6 (16.67%) 1
Leukopenia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	6 / 41 (14.63%) 14	0 / 6 (0.00%) 0
Ear and labyrinth disorders Tinnitus subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 1	4 / 41 (9.76%) 12	0 / 6 (0.00%) 0
Eye disorders Conjunctival haemorrhage subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	1 / 6 (16.67%) 1
Dry eye subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 41 (2.44%) 1	0 / 6 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	3 / 41 (7.32%) 10	0 / 6 (0.00%) 0
Gastrointestinal disorder subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 2	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Gastritis			

subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Dry mouth			
subjects affected / exposed	1 / 6 (16.67%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Diarrhoea			
subjects affected / exposed	2 / 6 (33.33%)	8 / 41 (19.51%)	3 / 6 (50.00%)
occurrences (all)	4	12	6
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	17 / 41 (41.46%)	1 / 6 (16.67%)
occurrences (all)	0	26	1
Ascites			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal rigidity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Abdominal pain upper			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	6	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	5 / 41 (12.20%)	0 / 6 (0.00%)
occurrences (all)	0	5	0
Melaena			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Lip dry			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Glossodynia			

subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	3 / 6 (50.00%)	19 / 41 (46.34%)	4 / 6 (66.67%)
occurrences (all)	10	56	4
Oral disorder			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	1 / 6 (16.67%)	14 / 41 (34.15%)	1 / 6 (16.67%)
occurrences (all)	2	22	4
Stomatitis			
subjects affected / exposed	1 / 6 (16.67%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Pancreatic failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatitis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Hypertransaminasaemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dry skin			



subjects affected / exposed	1 / 6 (16.67%)	3 / 41 (7.32%)	1 / 6 (16.67%)
occurrences (all)	1	4	1
Hyperhidrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	2 / 6 (33.33%)	4 / 41 (9.76%)	0 / 6 (0.00%)
occurrences (all)	4	4	0
Psoriasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	1 / 6 (16.67%)	5 / 41 (12.20%)	1 / 6 (16.67%)
occurrences (all)	1	7	1
Rash pruritic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Skin exfoliation			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	1 / 6 (16.67%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Rash maculo-papular			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Chronic kidney disease			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0

Genitourinary symptom subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Polyuria subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Urine odour abnormal subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Renal impairment subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 41 (2.44%) 1	0 / 6 (0.00%) 0
Endocrine disorders Hypophysitis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 4	0 / 41 (0.00%) 0	1 / 6 (16.67%) 1
Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 41 (2.44%) 1	0 / 6 (0.00%) 0
Musculoskeletal and connective tissue disorders Groin pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	9 / 41 (21.95%) 14	1 / 6 (16.67%) 2
Back pain subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 2	7 / 41 (17.07%) 8	0 / 6 (0.00%) 0
Chondropathy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Clubbing			

subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Myositis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Osteolysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Spinal pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 6 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Arthritis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Herpes zoster			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Localised infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mucosal infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	1 / 6 (16.67%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Clostridium difficile infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Oral candidiasis			
subjects affected / exposed	1 / 6 (16.67%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Candida infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Cellulitis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Sepsis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 6 (33.33%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	4	2	0
Urinary tract infection			
subjects affected / exposed	2 / 6 (33.33%)	6 / 41 (14.63%)	1 / 6 (16.67%)
occurrences (all)	2	9	1
Urosepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	1 / 6 (16.67%) 1
Oral herpes subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	1 / 6 (16.67%) 1
Influenza subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 41 (2.44%) 1	0 / 6 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	11 / 41 (26.83%) 19	1 / 6 (16.67%) 1
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 41 (4.88%) 2	0 / 6 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	3 / 41 (7.32%) 3	0 / 6 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 41 (4.88%) 4	0 / 6 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	4 / 41 (9.76%) 6	0 / 6 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 41 (2.44%) 1	0 / 6 (0.00%) 0
Hypocalcaemia			

subjects affected / exposed	1 / 6 (16.67%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Hypochloraemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Hypokalaemia			
subjects affected / exposed	2 / 6 (33.33%)	5 / 41 (12.20%)	0 / 6 (0.00%)
occurrences (all)	3	9	0
Hypomagnesaemia			
subjects affected / exposed	2 / 6 (33.33%)	4 / 41 (9.76%)	0 / 6 (0.00%)
occurrences (all)	2	5	0
Hyponatraemia			
subjects affected / exposed	0 / 6 (0.00%)	4 / 41 (9.76%)	1 / 6 (16.67%)
occurrences (all)	0	8	2
Hypophosphataemia			
subjects affected / exposed	3 / 6 (50.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	4	3	0
Increased appetite			
subjects affected / exposed	0 / 6 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 6 (16.67%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	1	0

<b>Non-serious adverse events</b>	Phase 1b Lead-in: Avelumab 800 mg + Gemcitabine/Cisplatin		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 13 (100.00%)		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Lymphoedema			

subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Superficial vein thrombosis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Thrombosis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
General disorders and administration site conditions			
Pain			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Oedema peripheral			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	3		
Mucosal inflammation			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Influenza like illness			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Fatigue			
subjects affected / exposed	8 / 13 (61.54%)		
occurrences (all)	16		
Extravasation			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Discomfort			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Chest pain			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Asthenia			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Thirst</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pyrexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Chills</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 13 (15.38%)</p> <p>3</p> <p>1 / 13 (7.69%)</p> <p>1</p> <p>1 / 13 (7.69%)</p> <p>1</p> <p>0 / 13 (0.00%)</p> <p>0</p>		
<p>Immune system disorders</p> <p>Cytokine release syndrome</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 13 (0.00%)</p> <p>0</p>		
<p>Reproductive system and breast disorders</p> <p>Pelvic pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 13 (0.00%)</p> <p>0</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnoea exertional</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Epistaxis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Haemoptysis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hypoxia</p>	<p>2 / 13 (15.38%)</p> <p>2</p> <p>1 / 13 (7.69%)</p> <p>1</p> <p>0 / 13 (0.00%)</p> <p>0</p> <p>0 / 13 (0.00%)</p> <p>0</p> <p>0 / 13 (0.00%)</p> <p>0</p>		



subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Pneumonitis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Productive cough			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Pulmonary embolism			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Depression			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Irritability			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Mood altered			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Anxiety			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	4		
Amylase increased			

subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	8		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Blood triglycerides increased			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Blood calcium increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Blood cholesterol increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Blood creatinine increased			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	16		
Blood pressure increased			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Body temperature increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Haemoglobin decreased			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	3		
Lymphocyte count decreased			
subjects affected / exposed	3 / 13 (23.08%)		
occurrences (all)	6		
Neutrophil count decreased			
subjects affected / exposed	3 / 13 (23.08%)		
occurrences (all)	12		
Platelet count decreased			
subjects affected / exposed	4 / 13 (30.77%)		
occurrences (all)	8		
Prothrombin time prolonged			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Troponin increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Weight decreased			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
White blood cell count decreased			
subjects affected / exposed	3 / 13 (23.08%)		
occurrences (all)	10		
Injury, poisoning and procedural complications			
Back injury			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Contusion			

subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Fall			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Femur fracture			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Infusion related reaction			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Pelvic fracture			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Procedural pneumothorax			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Skin abrasion			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Urinary tract stoma complication			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Cardiac disorders			
Tachycardia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Sinus bradycardia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Palpitations			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Intracardiac thrombus			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		

Atrial fibrillation subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Nervous system disorders			
Lethargy subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Ataxia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Cognitive disorder subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0		
Dizziness subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0		
Dizziness postural subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Dysgeusia subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2		
Headache subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Hypoaesthesia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Neuralgia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0		
Presyncope subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1		
Sciatica			

subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Taste disorder			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Tremor			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	4		
Neuropathy peripheral			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Lymphopenia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Neutropenia			
subjects affected / exposed	8 / 13 (61.54%)		
occurrences (all)	32		
Thrombocytopenia			
subjects affected / exposed	4 / 13 (30.77%)		
occurrences (all)	12		
Thrombocytosis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Anaemia			
subjects affected / exposed	10 / 13 (76.92%)		
occurrences (all)	26		
Haemolytic anaemia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Leukopenia			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	7		
Ear and labyrinth disorders			
Tinnitus			

subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Eye disorders			
Conjunctival haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Dry eye			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Abdominal distension			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Abdominal pain			
subjects affected / exposed	4 / 13 (30.77%)		
occurrences (all)	6		
Gastrointestinal disorder			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Gastritis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	4 / 13 (30.77%)		
occurrences (all)	5		
Dry mouth			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	4 / 13 (30.77%)		
occurrences (all)	11		
Constipation			

subjects affected / exposed	4 / 13 (30.77%)		
occurrences (all)	8		
Ascites			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Abdominal rigidity			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Melaena			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Lip dry			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Glossodynia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	9 / 13 (69.23%)		
occurrences (all)	27		
Oral disorder			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	5 / 13 (38.46%)		
occurrences (all)	8		
Stomatitis			



subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Pancreatic failure			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Hepatobiliary disorders			
Hepatitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Hypertransaminasaemia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Alopecia			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	4		
Dermal cyst			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Hyperhidrosis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Psoriasis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Rash			

subjects affected / exposed	3 / 13 (23.08%)		
occurrences (all)	5		
Rash pruritic			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Skin exfoliation			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	3 / 13 (23.08%)		
occurrences (all)	4		
Acute kidney injury			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Chronic kidney disease			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Genitourinary symptom			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Polyuria			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Urine odour abnormal			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Renal impairment			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		

Endocrine disorders			
Hypophysitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Hypothyroidism			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Hyperthyroidism			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Groin pain			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Arthralgia			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	4		
Back pain			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Chondropathy			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Clubbing			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Muscle spasms			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Musculoskeletal pain			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Myalgia			

subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Myositis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Osteolysis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Spinal pain			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Muscular weakness			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Flank pain			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Arthritis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Herpes zoster			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Localised infection			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Mucosal infection			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Conjunctivitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		

Clostridium difficile infection			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Oral candidiasis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Candida infection			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Cellulitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Sepsis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Urosepsis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Oral herpes			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		

Rhinitis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	3 / 13 (23.08%)		
occurrences (all)	3		
Hypercalcaemia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Hyperglycaemia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Hyperkalaemia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Hypertriglyceridaemia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	6		
Hypoalbuminaemia			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Hypocalcaemia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	2		
Hypochloraemia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Hypomagnesaemia			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Hyponatraemia			

subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Hypophosphataemia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Increased appetite			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Hyperuricaemia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 October 2018	<ul style="list-style-type: none"><li>• Introduction of a higher fixed dose of avelumab (based on US FDA feedback).</li><li>• Summary of Benefit/Risk Assessment was revised to include safety information from clinical trials for the 20 mg/kg every 2 weeks dose of avelumab.</li><li>• Biomarker Rationale was revised to include information about the use of biopsy data from subjects received the 1200 mg avelumab fixed dose.</li><li>• Updates regarding dose adjustments following dose delays due to toxicities, should start at the subsequent dose rather than "start of a subsequent cycle".</li><li>• Treatment after Initial Evidence of Radiological Disease Progression was updated to clarify that avelumab should be permanently discontinued in case of further disease progression.</li><li>• A clarification is also added about the timelines of subsequent radiologic imaging. Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Guidelines, update was added to clarify that all required scans must be done within 28 days prior to first dose of study treatment instead of prior to enrollment.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated since there was no need for further safety or efficacy data to be collected. The subjects having benefit from the investigational treatments have been moved to a continuation study NCT05059522

Notes: